Press Release: CaroGen : Hepatitis Drug Development Pipeline Review 2017: 182 Products in Development & 100 Companies Profiled - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Hepatitis Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering. Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; there are a total of seven products in development for hepatitis A, by four companies and two academic institutions. Beijing Minhai Biotechnology are fielding two pipeline products in this area, while all other companies are fielding only one. In hepatitis